People who want to get a Covid vaccination booster in the 2023-2024 campaign will have a choice between different vaccines with different technologies. But not all will be at the same time. Pfizer and BioNTech Laboratories were the first to receive marketing authorization from the European Medicines Agency (EMA) for an adapted version of their mRNA vaccine, Comirnaty.
This serum was developed to target the XBB.1.5 subgenus (nicknamed “Kraken”) of the Omicron variant. It will also offer protection against Eris (EG.5), the “descendant” of version XBB.1.9.2, which arrived in Europe this summer after being widely circulated in the United States and subsequently replaced XBB.1.5. The mutations Eris acquires make her more infectious and will also allow her to evade the immune response more easily. This suggests that people recently infected with XBB.1.5 may be reinfected…
Source: Le Figaro
I am John Sinkler, a professional writer and journalist for Buna Times. I specialize in writing about entertainment-related topics and have been doing so for several years now. My work has been featured on multiple platforms and I’m proud to say that it’s gained recognition from many people in the industry. Aside from working at Buna Times, I also write freelance articles for other publications.